News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
288,254 Results
Type
Article (15246)
Company Profile (298)
Press Release (272706)
Multimedia
Podcasts (98)
Webinars (12)
Section
Business (79976)
Career Advice (165)
Deals (13410)
Drug Delivery (44)
Drug Development (50839)
Employer Resources (31)
FDA (5905)
Job Trends (5189)
News (145428)
Policy (10082)
Tag
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (942)
Accelerated approval (29)
Adcomms (14)
Allergies (104)
Alliances (21765)
ALS (166)
Alzheimer's disease (1135)
Antibody-drug conjugate (ADC) (397)
Approvals (6195)
Artificial intelligence (362)
Autoimmune disease (253)
Automation (11)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (122)
Biotechnology (228)
Bladder cancer (121)
Brain cancer (58)
Breast cancer (425)
Cancer (4021)
Cardiovascular disease (293)
Career advice (154)
Career pathing (10)
CAR-T (276)
CDC (8)
Celiac Disease (1)
Cell therapy (731)
Cervical cancer (23)
Clinical research (44934)
Collaboration (1447)
Company closure (3)
Compensation (756)
Complete response letters (57)
COVID-19 (1126)
CRISPR (108)
C-suite (768)
Cystic fibrosis (120)
Data (5791)
Denatured (20)
Depression (115)
Dermatology (57)
Diabetes (316)
Diagnostics (1451)
Digital health (18)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (262)
Drug pricing (52)
Drug shortages (3)
Duchenne muscular dystrophy (275)
Earnings (32765)
Editorial (33)
Employer branding (4)
Employer resources (29)
Events (53492)
Executive appointments (698)
FDA (8093)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (17)
Frontotemporal dementia (31)
Funding (1195)
Gene editing (227)
Generative AI (33)
Gene therapy (606)
GLP-1 (561)
Government (1183)
Grass and pollen (3)
Guidances (175)
Healthcare (6727)
HIV (27)
Huntington's disease (51)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (91)
Immunology and inflammation (235)
Immuno-oncology (82)
Indications (130)
Infectious disease (1277)
Inflammatory bowel disease (183)
Inflation Reduction Act (10)
Influenza (55)
Intellectual property (203)
Interviews (18)
IPO (7368)
IRA (13)
Job creations (869)
Job search strategy (131)
JPM (41)
Kidney cancer (9)
Labor market (30)
Layoffs (253)
Leadership (14)
Legal (1403)
Liver cancer (46)
Longevity (24)
Lung cancer (537)
Lymphoma (299)
Machine learning (33)
Management (7)
Manufacturing (520)
MASH (161)
Medical device (2702)
Medtech (2723)
Mergers & acquisitions (6766)
Metabolic disorders (900)
mRNA (160)
Multiple sclerosis (124)
NASH (14)
Neurodegenerative disease (324)
Neuropsychiatric disorders (82)
Neuroscience (2304)
Neurotech (1)
NextGen: Class of 2026 (2038)
Non-profit (876)
Now hiring (39)
Obesity (399)
Opinion (142)
Ovarian cancer (186)
Pain (133)
Pancreatic cancer (231)
Parkinson's disease (301)
Partnered (12)
Patents (387)
Patient recruitment (503)
Peanut (49)
People (27199)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15937)
Phase 2 (20913)
Phase 3 (13170)
Pipeline (5933)
Policy (105)
Postmarket research (853)
Preclinical (6756)
Press Release (30)
Prostate cancer (199)
Psychedelics (58)
Radiopharmaceuticals (282)
Rare diseases (869)
Real estate (1458)
Recruiting (12)
Regulatory (10553)
Reports (20)
Research institute (982)
Resumes & cover letters (20)
Rett syndrome (35)
RNA editing (28)
RSV (24)
Schizophrenia (146)
Series A (234)
Series B (161)
Service/supplier (1)
Sickle cell disease (95)
Special edition (20)
Spinal muscular atrophy (125)
Sponsored (17)
Startups (2030)
State (1)
Stomach cancer (5)
Supply chain (39)
Tariffs (19)
The Weekly (76)
Vaccines (396)
Venture capital (88)
Weight loss (214)
Women's health (45)
Worklife (2)
Date
Today (38)
Last 7 days (423)
Last 30 days (1906)
Last 365 days (17838)
2026 (8356)
2025 (18098)
2024 (20536)
2023 (22411)
2022 (26821)
2021 (27803)
2020 (23355)
2019 (16223)
2018 (11736)
2017 (13750)
2016 (11838)
2015 (14348)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (72)
Alaska (2)
Arizona (82)
Arkansas (6)
Asia (18670)
Australia (3197)
California (8557)
Canada (2185)
China (1014)
Colorado (304)
Connecticut (322)
Delaware (293)
Europe (40149)
Florida (1103)
Georgia (251)
Hawaii (2)
Idaho (18)
Illinois (517)
India (46)
Indiana (198)
Iowa (8)
Japan (298)
Kansas (84)
Kentucky (11)
Louisiana (14)
Maine (12)
Maryland (886)
Massachusetts (6804)
Michigan (127)
Minnesota (308)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (6)
Nevada (47)
New Hampshire (22)
New Jersey (1947)
New Mexico (13)
New York (2131)
North Carolina (1001)
North Dakota (7)
Northern California (4335)
Ohio (214)
Oklahoma (11)
Oregon (23)
Pennsylvania (1581)
Puerto Rico (11)
Rhode Island (27)
South America (216)
South Carolina (12)
Southern California (3429)
Tennessee (50)
Texas (1168)
United States (28314)
Utah (118)
Virginia (175)
Washington D.C. (37)
Washington State (706)
West Virginia (1)
Wisconsin (57)
288,254 Results for "intellia therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene editing
Intellia heads to FDA after notching first late-stage win for in vivo gene editor
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for hereditary angioedema.
April 27, 2026
·
3 min read
·
Tristan Manalac
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme elevations in one patient, who died a few days later.
March 3, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Intellia Therapeutics to Participate in Upcoming Investor Conferences - May 5, 2026
May 5, 2026
·
1 min read
Press Releases
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 11, 2026
·
11 min read
Press Releases
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - April 29, 2026
April 29, 2026
·
5 min read
Press Releases
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
June 1, 2026
·
3 min read
Press Releases
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
May 4, 2026
·
1 min read
Press Releases
Intellia Announces Proposed Public Offering of Common Stock
April 28, 2026
·
5 min read
Press Releases
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
April 27, 2026
·
9 min read
Press Releases
Intellia Therapeutics to Participate in Upcoming March 2026 Investor Conferences
February 24, 2026
·
1 min read
1 of 28,826
Next
